- Record: found
- Abstract: found
- Article: not found
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Luis G Paz-Ares
1 ,
Filippo de Marinis ,
Mircea Dediu ,
Michael Thomas ,
Jean-Louis Pujol ,
Paolo Bidoli ,
Olivier Molinier ,
Tarini Prasad Sahoo ,
Eckart Laack ,
Martin Reck ,
Jesús Corral ,
Symantha Melemed ,
William John ,
Nadia Chouaki ,
Annamaria H Zimmermann ,
Carla Visseren-Grul ,
Cesare Gridelli
Aug 10 2013
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data.